Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 587-592

  Joergensen, Maiken Thyregod ^a   Brünner, Nils ^b   De Muckadell, Ove B Schaffalitzky ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carbohydrate antigen19 9; Matrix metalloproteinase 9; MMP 9; Pancreatic ductal adenocarcinoma; Receiver operating characteristic (ROC) curves; TIMP 1; Tissue inhibitor of metalloproteinases 1

Indexed keywords

CA 19-9 ANTIGEN; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 77950525615     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DiMagno EP, Reber HA and Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 117(6): 1464-1484, 1999.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58(2): 71-96, 2008.
3. Yeo CJ, Cameron JL, Lillemoe KD Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J and Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221(6): 721-731, 1995.
4. Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, Nishioka B, Miyamoto Y, Takano H, Yoshikawa T and Kondo M: Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 71(3): 140-146, 1999.
5. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z and Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47(20): 5501-5503, 1987.
6. Lamerz R: Role of tumour markers, cytogenetics. Ann Oncol 10(Suppl 4): 145-149, 1999.
7. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF and Toskes PP: Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 90(2): 343-349, 1986.
8. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 91(4): 439-442, 1997.
9. Bramhall SR, Neoptolemos JP, Stamp GW and Lemoine NR: Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182(3): 347-355, 1997.
10. Forster SJ, Talbot IC, Clayton DG and Critchley DR: Tumour basement membrane laminin in adenocarcinoma of rectum: an immunohistochemical study of biological and clinical significance. Int J Cancer 37(6): 813-817, 1986.
11. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284(5751): 67-68, 1980.
12. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2): 327-336, 1991.
13. Zervos EE, Shafii AE, Haq M and Rosemurgy AS: Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J Surg Res 84(2): 162-167, 1999.
14. Haq M, Shafii A, Zervos EE and Rosemurgy AS: Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res 60(12): 3207-3211, 2000.
15. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7(5): 728-735, 1995.
16. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8): 827-839, 2003.
17. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S and Tschesche H: The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 13(6): 1263-1269, 1994.
18. Bloomston M, Zervos EE and Rosemurgy AS: Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 9(7): 668-674, 2002.
19. Davidsen ML, Würtz SØ, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N and Lademann U: TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J of Cancer 95: 1114-1120, 2006.
20. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Brünner N and Stephens RW: Quantification of tissue inhibitor of metalloproteinases 1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80: 495-503, 1999.
21. Flahault A, Cadilhac M and Thomas G: Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol 58(8): 859-862, 2005.
22. Quantikine. Human MMP-9 (total) Immunoassy. Catalog Number DMP900, SMP900, PMD900. Minneapolis, USA, R&D Systems Inc., 2007.
23. Hoboken NJ, Wiley-Liss and Wiley J: TNM-Atlas: Illustrated guide to the TNM Classification of Malignant Tumors. 5th ed. Berlin, Springer-Verlag, PA: Ch Wittekind, 2005.
24. Altman GD: Practical Statistics for Medical Research. Chapter 14.4: Diagnostic tests. London. Champman & Hall, pp. 417-418, 1991.
25. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M and Adler G: Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 62(4): 407-413, 1995.
26. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL and Gibbs JF: Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 9(13): 4935-4943, 2003.
27. Sørensen NM, Schrol AS, Jensen V, Christensen IJ, Nielsen HJ and Brünner N: Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumor tissue extracts from patients with primary colorectal cancer. Scand J Gastroenterology 43: 186-191, 2008.
28. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y and Han JX: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8: 241-251, 2008.
29. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN and Goggins M: Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA 19-9. Clin Cancer Res 12: 442-446, 2006.